Press Releases
Epic Sciences Receives CAP Accreditation
SAN DIEGO, Jan 11, 2016 /PRNewswire/ -- Epic Sciences announced today that they have received notice of their accreditation from the College of American Pathologists (CAP) for its San Diego laboratory. The CAP Laboratory Accreditation Program is…
Circulating Tumor Cells Linked with Treatment Resistance and Response in Prostate Cancer Patients
SAN DIEGO, Jan. 4, 2016 /PRNewswire/ — Research teams at Memorial Sloan Kettering Cancer Center and Epic Sciences have found that greater diversity among circulating tumor cells (CTCs) in the blood of advanced prostate cancer patients predicts not only…
Epic Sciences Enters into 35th Pharma Collaboration to Advance Companion Diagnostics for New Targeted Therapeutics
SAN DIEGO, Dec. 11, 2015 /PRNewswire/ — Epic Sciences, a private biotech company that develops novel diagnostics to personalize and advance the treatment and management of cancer, announced today that it has signed its 35th collaboration agreement with…
Epic Sciences' Chief Scientific Officer Named Leading Global Thinker by Foreign Policy Magazine
SAN DIEGO, Dec. 1, 2015 /PRNewswire/ — Epic Sciences' Chief Scientific Officer Dena Marrinucci, Ph.D., was named today by Foreign Policy magazine as one of this year’s 100 Leading Global Thinkers. Marrinucci will be honored at a gala in Washington, D.C.…
Epic Sciences Partners with University of Pennsylvania's Abramson Cancer Center on Cancer Therapy Discoveries through Liquid Biopsy
SAN DIEGO, November 13, 2015 /PRNewswire/ -- Epic Sciences, Inc. announced today a collaboration with the Abramson Cancer Center of the University of Pennsylvania (Penn) on multiple studies to explore biomarkers, identified by analysis of circulating…
Circulating Tumor Cells (CTCs) in Patients’ Blood Detected by Epic Sciences are an “Accurate Representation” of Genetic Aberrations Found in Fresh Metastatic Tumor Samples
SAN DIEGO, Nov. 11, 2015 /PRNewswire/ -- Most men with advanced prostate cancer, whether initially treated through surgical or chemical castration, eventually develop drug-resistant tumors. Monitoring for drug resistant genetic mutations could inform…
Epic Sciences’ Platform Capable of Single Cell CTC Identification Sequencing in Late Stage, Metastatic Cancer
SAN DIEGO, November 2, 2015 — After successive cancer therapies, multiple subpopulations of cancer cells arise, each with divergent genetic aberrations that may confer drug resistance or susceptibility. Tissue biopsies may not detect these subpopulations,…
Epic Sciences Present at World CDx Boston 2015
SAN DIEGO – September 2, 2015 -- Epic Sciences, Inc. (“Epic Sciences”), announced today that Murali Prahalad, Ph.D., president and CEO, is scheduled to present at the World CDx Boston 2015, taking place at the Hilton Boston Logan Airport, September 8 –…
Epic Sciences Appoints Dave Henderson as Chief Information Officer
SAN DIEGO – August 26, 2015 - Epic Sciences, Inc. (“Epic Sciences”), announced today the appointment of Dave Henderson as Epic Sciences’ chief information officer (CIO). Mr. Henderson has more than 20 years of experience in information technologies at…
Epic Sciences’ Dr. Dena Marrinucci is Recognized as an Honoree of MIT Technology Review’s Annual Innovators Under 35 List
Today, MIT Technology Review revealed its annual list of Innovators Under 35. For over a decade, the global media company has recognized a list of exceptionally talented technologists whose work has great potential to transform the world. For her work in…